Posts

Posted on

Viasat to Acquire RigNet in All-Stock Transaction

– Strategic combination expands Viasat’s commercial connectivity offering

– RigNet stockholders to receive 0.1845 shares of Viasat stock per RigNet share, a 17.9% premium over both companies’ 20-day volume-weighted average prices

– RigNet’s Board of Directors and largest stockholder support transaction

– Transaction expected to close by mid-calendar year 2021

– Investor Conference Call Scheduled for Monday, December 21, 2020 at 8:30 a.m. Eastern Time

PR Newswire

HOUSTON, Dec. 21, 2020 /PRNewswire/ — RigNet, Inc. (NASDAQ: RNET, the “Company”), a leading provider of ultra-secure, intelligent networking solutions and specialized applications, announced that its Board of Directors has unanimously approved the Company’s entry into a definitive agreement whereby Viasat Inc. (NASDAQ: VSAT) will acquire RigNet in an all-stock transaction representing an enterprise value of $222 million, including RigNet’s net debt as of September 30, 2020, based on the closing price of Viasat common stock on December 18, 2020.  The strategic combination creates a vertically integrated communications company serving customers in industries that include government, airlines, residential, energy, and others by providing cutting-edge connectivity from the satellite to the end customer and delivering premier managed communications services coupled with a suite of advanced application solutions that include real-time machine learning and advanced cybersecurity.

“We are excited to announce this strategic combination with Viasat, a leading global innovator in satellite technology and service delivery,” said Steven Pickett, RigNet’s President and Chief Executive Officer.  “This is a transformative merger with a company that is highly diversified across a number of important verticals, maintains a strong balance sheet, and is planning to expand its global satellite coverage significantly through its upcoming ViaSat-3 constellation.  We believe the merger will create new opportunities for the combined companies to serve customers even better in energy and to expand more rapidly into other vertical markets.  The combined companies will also be able to further accelerate the growth of RigNet’s industry-leading AI-backed machine learning business, Intelie, and our other specialized apps, across a broader customer base than RigNet could have reached independently.”

Rick Baldridge, Viasat’s President and Chief Executive Officer, commented, “We believe that RigNet will be a wonderful addition to Viasat’s expanding commercial connectivity program.  We admire what Steve and his team have built over the last several years, performing well relative to peers in the energy sector, moving up the stack, and delivering some truly exceptional capabilities that are unique among their competitors.  We see RigNet as an important element in our global expansion efforts and expect to achieve accretive synergies that go well beyond traditional cost savings.  There is tremendous upside potential here, and we look forward to closing the acquisition as quickly as possible so both companies and our stockholders can realize the benefits of the combination and fulfill our vision of connecting everyone, anywhere.”

Transaction Details

Under the terms of the agreement, RigNet’s stockholders will receive a fixed exchange ratio of 0.1845 shares of Viasat stock for each RigNet share owned.  Based on the parties’ volume weighted average prices (“VWAPs”) for the 20 trading days ending on December 18, 2020, the transaction represents a 17.9% premium for RigNet’s stockholders.  Upon closing RigNet stockholders are expected to own approximately ~5.7% of Viasat’s outstanding common stock. The all-stock transaction is intended to be tax-free to RigNet stockholders.

The transaction, which is expected to close by mid-calendar year 2021, is subject to customary closing conditions and regulatory approvals, including the approval of RigNet’s stockholders.  An affiliate of KKR & Co. Inc., RigNet’s largest shareholder, has entered into a support agreement in which it has agreed to vote in favor of approving the merger, subject to certain conditions.

Advisors

Lazard Middle Market LLC and Baker Botts L.L.P. acted as RigNet’s financial and legal advisors, respectively.  LionTree Advisors LLC and Latham & Watkins LLP acted as Viasat’s financial and legal advisors, respectively.

Conference Call

RigNet will host a call for investors at 8:30 a.m. Eastern Time (7:30 a.m. Central Time) on December 21, 2020 with Steven Pickett and Rick Baldridge from Viasat to discuss the transaction.  The call may be accessed live over the telephone by dialing +1 (877) 640-9809, or, for international callers, +1 (914) 495-8528 using the conference ID: 9486405. Interested parties may also listen to a simultaneous webcast of the conference call by logging onto RigNet’s website at www.rig.net in the Investors –Webcasts andPresentations section.  A replay of the conference call webcast will also be available on our website for approximately thirty days following the call.  You may also access the replay by dialing +1 (855) 859-2056 in the U.S. or +1 (404) 537-3406 internationally and entering the conference ID: 9486405.

About RigNet

RigNet (NASDAQ: RNET) delivers advanced software and communications infrastructure that allow our customers to realize the business benefits of digital transformation. With world-class, ultra-secure solutions spanning global IP connectivity, bandwidth-optimized OTT applications, IIoT big data enablement, and industry-leading machine learning analytics, RigNet supports the full evolution of digital enablement, empowering businesses to respond faster to high priority issues, mitigate the risk of operational disruption, and maximize their overall financial performance. RigNet is headquartered in Houston, Texas with operations around the world. 

About Viasat

Viasat is a global communications company that believes everyone and everything in the world can be connected. For more than 30 years, Viasat has helped shape how consumers, businesses, governments and militaries around the world communicate. Today, the Company is developing the ultimate global communications network to power high-quality, secure, affordable, fast connections to impact people’s lives anywhere they are—on the ground, in the air or at sea. To learn more about Viasat, visit: www.viasat.com, go to Viasat’s Corporate Blog, or follow the Company on social media at: Facebook, Instagram, LinkedIn, Twitter or YouTube.

Important Additional Information and Where to Find It

This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, THE REGISTRATION STATEMENT AND OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC REGARDING THE TRANSACTION CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. These documents (when they become available) will contain important information about the proposed transaction that should be read carefully before any decision is made with respect to the proposed transaction. These materials will be made available to stockholders of RigNet at no expense to them.  Investors will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by RigNet and/or Viasat through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by RigNet will be available free of charge on RigNet’s internet website at http://www.rig.net. Copies of the documents filed with the SEC by Viasat will be available free of charge on Viasat’s internet website at http://www.viasat.com.  

Participants in the Solicitation

Viasat, RigNet, their respective directors and certain of their respective executive officers may be considered, under SEC rules, participants in the solicitation of proxies from the stockholders of RigNet in connection with the proposed transaction. Information about the directors and executive officers of RigNet is set forth in its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 11, 2020, and its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on March 30, 2020. Information about the directors and executive officers of Viasat is set forth in its Annual Report on Form 10-K for the year ended March 31, 2020, which was filed with the SEC on May 29, 2020, and its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on July 23, 2020. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests in the transaction, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC when they become available.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 – that is, statements related to future, not past, events. Forward-looking statements may include comments about the expected benefits of the transaction, potential value to be realized by RigNet’s stockholders, timing of and ability to ultimately close the transaction, Viasat’s financial position and long-term strategy, the nature of any synergies, and other similar statements. Forward-looking statements are based on current expectations and include any statement that does not directly relate to a current or historical fact.  In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as “anticipate,” “believe,” “intend,” “will,” “expect,” “plan” or other similar words. These forward-looking statements involve certain risks and uncertainties, including those risks set forth in Item 1A – Risk Factors of the Company’s most recent 10-K filing, and Item 1A- Risk Factors of the Company’s 10-Q filing for the quarter ended March 31, 2020, filed with the SEC on Monday, May 11, 2020, and ultimately may not prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. For further discussion of risks and uncertainties, individuals should refer to RigNet’s SEC filings. RigNet undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

For more information on RigNet, please visit www.rig.net. RigNet is a registered trademark of RigNet, Inc.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viasat-to-acquire-rignet-in-all-stock-transaction-301196519.html

SOURCE RigNet, Inc.

Posted on

Wyoming, Idaho, and Tennessee Ranked the Riskiest States to Travel to During the Holidays

PR Newswire

SEATTLE, Dec. 21, 2020 /PRNewswire/ — QuoteWizard®, a LendingTree company, and one of the nation’s leading online insurance marketplaces released a report on holiday travel risk factors to see which states were considered riskier than others to visit this holiday season.

With holiday travel estimated to see strong numbers, dangers on the roads, and COVID-19 make for serious risks while seeing friends and family this year. Depending on where you’re traveling, those risks can be greater than other destinations.

Visit the full report here, https://quotewizard.com/news/posts/riskiest-places-to-travel-during-the-holidays

Key Findings:

  • Over 3,100 deaths were recorded on Thanksgiving Day, breaking the daily COVID-19 death record.
  • In 2019, the National Highway Traffic Safety Administration (NHTSA) estimated that 799 auto fatalities would occur across the U.S. over the Christmas and New Year holiday.
  • West Virginia, Kentucky and Alabama have the most at-risk seniors with underlying health conditions.
  • North Dakota, Rhode Island and South Dakota have the highest COVID-19 cases and death rates per 100,000 in the last seven days.
  • Nevada, Wyoming and Georgia have the fewest vaccinated adults, causing more concern for the seasonal flu as well as a higher adoption rate for the COVID-19 vaccine.
  • Wyoming, Virginia and Colorado ranked 2020’s worst-driving states in our fifth annual Best and Worst Drivers by State.

Methodology

QuoteWizard analyzed three driving and three health metrics to determine which states are the riskiest for pandemic holiday travel. In addition, we looked at the most recent (Tuesday, December 15) CDC data on United States COVID-19 Cases and Deaths by State in the last seven days per 100,000 people from all 50 states. Each metric was then ranked on a scale of 1 to 50, representing the safest to riskiest conditions for specific state travel. We then determined each state’s safety ranking by totaling across all metric scores to calculate its overall ranking and used the resulting scores to rank-order each of the states.

  • Dangerous driving states – These rankings are compiled from QuoteWizard’s annual best and worst driver study. Each state’s driver quality ranking is based on the rate of accidents, speeding tickets and DUIs.
  • Seniors with underlying health conditions – We analyzed CDC prevalence data that looks at seniors with high-risk COVID-19-related health issues that include diabetes, cardiovascular disease, chronic obstructive pulmonary disease (COPD) and asthma. Adult vaccination rates – QuoteWizard analyzed the Commonwealth Fund’s Health System Data on adults with age-appropriate vaccinations.
  • Hospital capacity – To evaluate health care capacity, we analyzed Health and Human Services (HHS) and Kaiser Family Foundation data, looking at IUC beds and physicians per 1,000 people in each state.
  • COVID-19 cases and death rates – We looked at the most recent (Monday, December 14) CDC data on United States COVID-19 Cases and Deaths by State in the last seven days per 100,000 people

About QuoteWizard QuoteWizard (quotewizard.com) is an insurance comparison marketplace for consumers looking to save on insurance. QuoteWizard provides consumers with direct access to thousands of qualified agents in all 50 states, as well as major carriers, who offer personalized quotes and the opportunity to save up to 40% on auto, home, health, and life insurance. Agents and carriers, in turn, benefit from millions of highly qualified leads, calls, and traffic to their site. Based in Seattle, QuoteWizard was founded in 2006.

For more information, go to quotewizard.com, like our Facebook page and/or follow us on Twitter @quotewizard.

About LendingTree LendingTree (NASDAQ: TREE) is the nation’s leading online marketplace that connects consumers with the choices they need to be confident in their financial decisions. LendingTree empowers consumers to shop for financial services the same way they would shop for airline tickets or hotel stays, comparing multiple offers from a nationwide network of over 500 partners in one simple search, and can choose the option that best fits their financial needs. Services include mortgage loans, mortgage refinances, auto loans, personal loans, business loans, student refinances, credit cards and more. Through the My LendingTree platform, consumers receive free credit scores, credit monitoring, and recommendations to improve credit health. My LendingTree proactively compares consumers’ credit accounts against offers on our network and notifies consumers when there is an opportunity to save money. In short, LendingTree’s purpose is to help simplify financial decisions for life’s meaningful moments through choice, education and support. LendingTree, LLC is a subsidiary of LendingTree, Inc.

Media Contacts:

Emily: [email protected]

Nathan: [email protected]

Related Links
https://quotewizard.com
https://quotewizard.com/news/posts/riskiest-places-to-travel-during-the-holidays

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wyoming-idaho-and-tennessee-ranked-the-riskiest-states-to-travel-to-during-the-holidays-301196378.html

SOURCE QuoteWizard

Posted on

Healthcare Trust Announces Series A Preferred Stock Dividend

PR Newswire

NEW YORK, Dec. 21, 2020 /PRNewswire/ — Healthcare Trust, Inc. (Nasdaq: HTIA) (“HTI”) announced today that it intends to continue to pay dividends on a quarterly basis on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) at an annualized rate of $1.84375 per share or $0.4609375 per share on a quarterly basis.  Dividends on the Series A Preferred Stock are payable in arrears to Series A Preferred Stock holders of record at the close of business on the applicable record date and payable on the 15th day of the first month of each fiscal quarter (or, if not a business day, the next succeeding business day).

Accordingly, HTI declared a dividend of $0.4609375 per share of Series A Preferred Stock payable on January 15, 2021 to Series A Preferred Stock holders of record at the close of business on January 5, 2021.

About Healthcare Trust, Inc.

Healthcare Trust, Inc. (Nasdaq: HTIA) is a publicly registered real estate investment trust focused on acquiring a diversified portfolio of healthcare real estate, with an emphasis on seniors housing and medical office buildings, located in the United States. Additional information about HTI can be found on its website at www.healthcaretrustinc.com.

Important Notice

The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results or events to be materially different. The words “anticipates,” “believes,” “expects,” “estimates,” “projects,” “plans,” “intends,” “may,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of HTI’s control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the potential adverse effects of the ongoing global COVID-19 pandemic, including actions taken to contain or treat COVID-19, on HTI, HTI’s tenants, HTI’s operators and the global economy and financial markets and that the information about rent collections may not be indicative of any future period, as well as those risks and uncertainties set forth in the Risk Factors section of HTI’s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 24, 2020, HTI’s most recent Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020, filed on May 15, 2020, August 14, 2020, and November 16, 2020, respectively, HTI’s Registration Statement on Form S-11 filed with the SEC on September 15, 2020 and all other filings with the SEC after that date, as such risks, uncertainties and other important factors may be updated from time to time in HTI’s subsequent reports. Further, forward looking statements speak only as of the date they are made, and HTI undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results, unless required to do so by law.

Contact

Investors and Media:
Email: [email protected]
Phone: (866) 902-0063

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/healthcare-trust-announces-series-a-preferred-stock-dividend-301196222.html

SOURCE Healthcare Trust, Inc.

Posted on

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–
Regulatory News:

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies for the treatment of a variety of medical conditions including infectious diseases, announced that the company, through its wholly owned subsidiary Aptorum International Limited, has submitted a Clinical Trial Application (CTA) with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA). Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers.

Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented: “Further to our previous update in September 2020, we are pleased to announce this CTA submission which represents a major development milestone for our ALS-4 antimicrobial program. ALS-4 is a novel small molecule adopting an anti-virulence (non-antibiotic) approach to address the growing unmet medical needs of infections caused by Staphylococcus aureus. ALS-4 is an orally administered drug and thereby aligning with global healthcare policy to actively promote the switch from an IV to oral based antimicrobial treatment1,2,3. As shown in our internal preclinical data and subject to further clinical trials, ALS-4 can be potentially used on a standalone basis or in combination with existing antibiotics (for example, vancomycin) with the aim to reduce mortality and morbidity of the infected patients especially in severe cases. We believe that our orally administered ALS-4 drug can potentially also tackle a variety of infections caused by Staphylococcus aureus, including (but not limited to) MRSA bacteremia and skin & soft tissue infections, subject to the respective clinical trials.”

The Phase 1 clinical trial is planned to be conducted in Canada and targeted to recruit up to 48 and 32 healthy volunteers for the single-ascending dose (SAD) and multiple- ascending dose (MAD) cohorts, respectively. The primary objective of the trial is to evaluate the safety and tolerability of SAD and MAD of ALS-4 administered orally to healthy subjects. The secondary objective is to assess the pharmacokinetic profile of SAD and MAD of ALS-4 administered orally to healthy subjects.

About ALS-4

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel first-in-class orally administered small molecule drug based on an anti-virulence (non-antibiotic) approach targeting Staphylococcus aureus including MRSA. ALS-4 targets to inhibit the virulence properties of the bacteria and render them highly susceptible to the host’s immune clearance and also potentially provide added benefits in combination with existing antibiotics.

About Aptorum Group

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a biopharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The pipeline of Aptorum is also enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through programs such as the systematic screening of existing approved drug molecules and microbiome-based research platform for treatments of metabolic diseases. In addition to the above main focus, the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. Aptorum also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future, as well as the prospectus that received the French Autorité des Marchés Financiers visa n°20-352 on 16 July 2020.

As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

This press release is provided “as is” without any representation or warranty of any kind.

1https://www.gloshospitals.nhs.uk/gps/antimicrobial-resources/adult-antibiotic-treatment-guidelines-site-infection/iv-oral-switch-guideline/ and https://www.dbth.nhs.uk/wp-content/uploads/2017/10/IV-to-oral-switch-and-5-day-stop-policy.pdf

2https://hgs.uhb.nhs.uk/wp-content/uploads/Guidelines-for-Antimicrobial-Prescribing-v5.0.pdf

3https://www.jwatch.org/na48403/2019/02/12/sequential-intravenous-oral-treatment-mrsa-bacteremia

Inquiries:

Aptorum Group Limited

Investor Relations Department:

[email protected]

+44 20 80929299

Redchip – Financial Communications United States

Investor relations

Dave Gentry

[email protected]

+1 407 491 4498

Actifin – Financial Communications Europe

Investor relations

Ghislaine Gasparetto

[email protected]

+33 1 56 88 11 22

KEYWORDS: North America France United States United Kingdom Europe New York

INDUSTRY KEYWORDS: Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo
Posted on

ICICI Bank Canada Visa* Debit Card launched

ICICI Bank Canada Visa* Debit Card launched

  • The card enables customers to shop online and at merchant outlets across the world on Visa network
  • Allows quick contactless payments at PoS machines across the country

TORONTO–(BUSINESS WIRE)–
ICICI Bank Canada today announced the launch of a debit card. Named, ‘ICICI Bank Canada Visa Debit Card’, it offers customers an unparalleled benefit of online shopping, purchasing at millions of retail outlets across the world and making quick contactless payments at Point of Sale (PoS) machines across Canada. This card also empowers customers to withdraw cash from thousands of Automated Banking Machines (ABMs) in the country without surcharge#.

Further, the Bank offers customers the ease of activating the card and blocking/unblocking it with a few simple clicks on its mobile banking app, ‘ICICI Bank Canada iMobile app’ and online banking platform. It is the first card in Canada that enjoys the combined strength of Visa*,Interac† and THE EXCHANGE® Network as it is powered by these three large networks.

Commenting on the launch, Mr. Sandeep Goel, President and CEO, ICICI Bank Canada, said, “At ICICI Bank Canada, it is our constant endeavor to bring forth innovative banking solutions for our customers. We are delighted to join hands with our long standing partner Visa for the launch of this unique debit card. During the ongoing pandemic, we are witnessing an accelerated shift of consumers towards the digital world, resulting in record growth in online sales. We believe that this card will act as an enabler to provide our customers with a frictionless payment experience across channels.”

ICICI Bank Canada and Everlink Payment Services Inc. are jointly spearheading the Visa debit card adoption for other financial institutions to drive digital payments growth in Canada.

“We are pleased to work with ICICI Bank Canada to offer its customers increased choice, flexibility and security through access to Visa’s leading debit capabilities,” said Ms.Stacey Madge, President & Country Manager, Visa Canada. “As spending habits continue to show a preference for online shopping, customers of ICICI Bank Canada will now have more ways to shop online with ‘ICICI Bank Canada Visa Debit Card’, accepted by millions of merchants worldwide.”

“It has been a pleasure to work with ICICI Bank Canada to bring ‘ICICI Bank Canada Visa Debit Card’ to market and we’re very excited about the benefits this program will bring,” said Mr.Mark Ripplinger, President and CEO of Everlink. “We feel the delivery of this program is apt in time amidst the challenges of the COVID-19 pandemic. Indeed, over the last few years we have witnessed the rapid shift in card payments from brick and mortar stores to online. This has only been accelerated over the last eight months as cardholders seek safer ways to shop.”

“We are excited to see ICICI Bank Canada take the lead in offering this first-to-market service to their customers. THE EXCHANGE Network saves Canadian cardholders millions of dollars each year in ABM surcharge fees and we are thrilled that our longstanding member, ICICI Bank Canada, is extending our unique network value to its ICICI Bank Canada Visa Debit Card cardholders,” said Mr. Andrew Obee, President & CEO of FICANEX.

Key benefits of the card:

Worldwide acceptance: Customers can use the card to shop online at more than 1.5 million merchants and at 55 million international retailers worldwide, wherever Visa is accepted.

Robust security: Robust Visa security measures and 24×7 fraud monitoring make the online transactions even more safe and secure.

Manage cards feature: This feature enables customers to activate the card or block/unblock it digitally, using ICICI Bank Canada iMobile app and online banking platform.

PoS and ABMs: The card can be used at more than 450,000 PoS locations in Canada and offers surcharge-free access to thousands of ABM machines in the country#.

An existing customer of the Bank can apply for this card by visiting any ICICI Bank Canada branch or contacting the customer contact center.

To learn more about the ICICI Bank Canada Visa Debit Card, please click here.

About ICICI Bank Canada

ICICI Bank Canada is a wholly-owned subsidiary of ICICI Bank Limited, which has its headquarters in Mumbai, India. ICICI Bank Limited (BSE: ICICIBANK, NSE: ICICIBANK and NYSE: IBN) is a leading private sector bank in India. The Bank’s consolidated total assets stood at US$200.08 billion as at September 30, 2020. Active in all provinces and territories, ICICI Bank Canada conducts business as a full service direct bank under Canada’s Bank Act. Visit icicibank.ca to learn more

About Visa Inc.

Visa Inc. (NYSE: V) is a world leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network – enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. Our relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit visa.ca, usa.visa.com/visa-everywhere/blog.html and @VisaCA.

*VISA is a registered trademark of Visa International Service Association and used under license

†Interac and Interac Flash are registered trademark owned by Interac Corp.., used under license

®THE EXCHANGE marks are licensed for use in Canada by FICANEX Services Limited Partnership

# Surcharge free withdrawals only on THE EXCHANGE Network

Shweta Patheja

ICICI Bank Canada

+1 (416) 885 2994

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Other Professional Services Professional Services Technology Online Retail Consumer Other Consumer Retail Other Technology

MEDIA:

Logo
Logo
Posted on

Clean Energy and Total to Develop Additional Carbon-Negative Fuel and Infrastructure

Clean Energy and Total to Develop Additional Carbon-Negative Fuel and Infrastructure

Up to $145 Million Available for Upstream Renewable Natural Gas Projects and Downstream Fueling

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–
Clean Energy Fuels Corp. (Nasdaq: CLNE) and its largest shareholder, Total S.E., today announced a memorandum of understanding to create a 50/50 joint venture to develop carbon-negative renewable natural gas (RNG) production facilities in the United States, as well as credit support to build additional downstream RNG fueling infrastructure. Total will provide $50 million and Clean Energy $30 million for the proposed joint venture and Total will be providing credit support of $65 million to support Clean Energy development in the RNG value chain, including $45 million for contracted RNG fueling infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201221005177/en/

The companies have already partnered to expand the use of RNG in the heavy-duty truck market with its Zero Now program, which allows fleets to purchase natural gas trucks for the same price as diesel trucks. The demand for carbon-negative RNG, which is derived from dairies and other agricultural facilities, has rapidly accelerated through the Zero Now program with trucking companies such as Kenan Advantage, KeHE Distributors, Estes Express Lines, Tradelink Transport, among many others, taking advantage of the economic savings while powering their new fleets with the cleanest fuel in the world.

Negative-carbon RNG is produced when carbon emissions are captured from dairies and turned into a transportation fuel, reducing the harmful effects on long-term climate change. As a result, the California Air Resources Board gives these carbon-negative RNG projects a carbon intensity (“CI”) Score (gCO2e/MJ) of -250 (or lower) compared to 97 for diesel and 46 for electric batteries. Clean Energy is the largest provider of RNG as a transportation fuel in the United States and Canada, and the largest RNG fuel provider under the California LCFS program.

“We are very fortunate to have a partner in Total that is so supportive on a number of levels,” said Andrew J. Littlefair, CEO and president of Clean Energy. “Both our companies have recognized the enormous opportunity that a carbon-negative fuel can play in our ambitious efforts to combat climate change. This new agreement will allow Clean Energy to increase the flow of low-CI RNG as the demand expands, as well as the capital to build new fueling stations for additional contracted fleets.”

Clean Energy’s goal is to meet the rapidly growing demand by customers for carbon-negative RNG and to deliver 100% Redeem™ branded RNG to its entire fueling infrastructure by 2025, which it is well on its way to achieving.

About Clean Energy

Clean Energy Fuels Corp. is the leading provider of the cleanest fuel for the transportation market in the United States and Canada. Through its sales of Redeem™ renewable natural gas (RNG), which is derived from capturing biogenic methane produced from decomposing organic waste, Clean Energy allows thousands of vehicle fleets, from airport shuttles to city buses to waste and heavy-duty trucks, to reduce their amount of climate-harming greenhouse gas by at least 70% and even up to 300% depending on the source of the RNG. Clean Energy can deliver Redeem through compressed natural gas (CNG) and liquified natural gas (LNG) to its network of approximately 540 fueling stations across the U.S. and Canada. Clean Energy builds and operates CNG and LNG fueling stations for the transportation market, owns natural gas liquefication facilities in California and Texas, and transports bulk CNG and LNG to non-transportation customers around the U.S. For more information, visit www.CleanEnergyFuels.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks, uncertainties and assumptions, such as statements regarding, among other things: the completion and timing of the transaction contemplated by the Memorandum of Understanding (“MOU”); Clean Energy’s plans for its RNG business; increased market adoption of carbon-negative RNG as a vehicle fuel; growth in Clean Energy’s customer base for its Redeem™ RNG vehicle fuel; the strength of Clean Energy’s vehicle fueling infrastructure and its ability to leverage this infrastructure to increase sales of Redeem™ vehicle fuel and to deliver 100% Redeem™ branded RNG to its entire fueling infrastructure by 2025; the benefits of RNG as an alternative vehicle fuel, including economic and environmental benefits; and growth in and certainty of supply of RNG. Actual results and the timing of events could differ materially from those expressed in or implied by these forward-looking statements as a result of a variety of factors, including, among others: Clean Energy’s and TOTAL’S ability to close the joint venture contemplated by the MOU on the timeline anticipated or at all; supply, demand, use and prices of crude oil, gasoline, diesel, natural gas and alternative fuels, as well as heavy-duty trucks and other vehicles powered by these fuels; the willingness of fleets and other consumers to adopt RNG as a vehicle fuel; and general economic, political, regulatory, market and other conditions. The forward-looking statements made in this press release speak only as of the date of this press release and Clean Energy undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Additionally, the reports and other documents Clean Energy files with the SEC (available at www.sec.gov) contain additional information on these and other risk factors that may cause actual results to differ materially from the forward-looking statements contained in this press release.

Clean Energy Contact:

Raleigh Gerber

949-437-1397

[email protected]

Investor Contact:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Environment Alternative Vehicles/Fuels Trucking Automotive Transport Oil/Gas Automotive Manufacturing Manufacturing Energy Fleet Management

MEDIA:

Logo
Logo
Logo
Logo
Posted on

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma

UTHealth in Houston and Athersys Announce Commencement of Patient Enrollment in a Phase 2 Trial Evaluating MultiStem® Cell Therapy in Trauma

Initiation of innovative clinical trial focused on reducing complications and enhancing patient recovery following trauma at Memorial Hermann-Texas Medical Center, a major Level 1 Trauma Center, with funding from MTEC

CLEVELAND–(BUSINESS WIRE)–
The University of Texas Health Science Center at Houston (UTHealth) and Athersys, Inc. (NASDAQ: ATHX) announced today that the first patient has been enrolled in a clinical study evaluating MultiStem® cell therapy for the potential early treatment of traumatic injuries and the subsequent complications that result. The MATRICS-1 (MultiStem Administration for Trauma Related Inflammation and Complications) study is being conducted at Memorial Hermann-Texas Medical Center, one of the busiest Level 1 trauma centers in the United States.

The Phase II randomized, double-blinded, placebo-controlled study is being funded by a grant award from the Medical Technology Enterprise Consortium (MTEC) awarded to McGovern Medical School at UTHealth. In addition, the Memorial Hermann Foundation is providing additional funding. Athersys is the trial sponsor and is supplying the investigational clinical product for the conduct of the trial, as well as providing regulatory and operational support. Dr. Charles S. Cox Jr., the George and Cynthia Mitchell Distinguished Chair in Neurosciences in the Department of Pediatric Surgery at McGovern Medical School at UTHealth and co-Director of the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center, is serving as the principal investigator.

The objective of the clinical study is to evaluate the safety and efficacy of MultiStem in the treatment of injured patients with severe hemorrhage for the prevention and mitigation of complications that can result following severe traumatic injury. The single-center trial will enroll up to 156 subjects. Subjects will be randomized and administered either placebo or MultiStem cellular therapy following admission to the intensive care unit and after initial resuscitation has concluded and stabilizing procedures have been performed to stop bleeding. All study subjects will also receive all standard of care treatments for their injuries.

“The use of this treatment strategy leverages a long legacy of investigation into the common mechanism of action of down-regulation of the inflammatory response to injury and how it mitigates complications of trauma,” commented Dr. Charles S. Cox Jr., Principal Investigator at UTHealth.

Although the causes of traumatic injury are diverse, evidence suggests the hyperinflammatory response following these injuries is similar to other causes of acute tissue injury, such as acute ischemic stroke, acute respiratory distress syndrome (ARDS), traumatic brain injury and spinal cord injury. Activation and mobilization of the peripheral immune system after an injury contributes to local secondary tissue damage. This immune activation may also result in systemic inflammatory response syndrome (SIRS), which can leave the patient susceptible to a range of complications, including secondary infections and organ failure conditions, that prevent or complicate recovery. Results of pre-clinical injury models and clinical data from human trials in other indications suggest early administration of MultiStem cells may reduce the inflammatory cascade that ensues after severe acute injury by reducing the number of inflammatory systemic immune cells in and around sites of injury, and by decreasing immune cell activation and the release of inflammatory cytokines in response to circulating products of tissue injury. The study will evaluate whether MultiStem’s modulation of these immune responses to traumatic injury can mitigate secondary tissue injury, organ failure states, and other complications that impede patient recovery following severe traumatic injury.

“Prior research conducted in collaboration with UTHealth suggests that administration of MultiStem following traumatic injury has the potential to downregulate the resultant hyperinflammatory cascade, and upregulate key repair mechanisms, improving overall recovery. Athersys is very appreciative of the support provided by MTEC and the Memorial Hermann Foundation for the conduct of this study and the tremendous amount of hard work and effort we’ve experienced in this collaboration with researchers, clinicians and staff at UTHealth,” commented Dr. Robert W. Mays, Vice President of Regenerative Medicine and Head of Neuroscience Programs at Athersys. “We are pleased to enroll the first patient and look forward to evaluating the effects of MultiStem cellular therapy on patient outcomes. Severe trauma and the related downstream pathologies it can initiate is a clear unmet medical need of significance.”

According to the Centers for Disease Control (CDC), trauma is the leading cause of death for individuals under the age of 45 and the third leading cause of death in the U.S., accounting for approximately 180,000 fatalities each year. It is also a leading cause of serious disability, especially among young people and members of the military that suffer trauma. According to independent research there are more than 31 million non-fatal injuries treated in U.S. hospitals each year.1

Athersys released an educational video today to provide additional information about this first-ever clinical study evaluating a cell therapy for treatment of traumatic injuries. The video features interviews with the clinical investigators that will be participating in the trial and other key personnel at Athersys. The video may be assessed from the Athersys website at www.athersys.com or at the following YouTube link: https://youtu.be/qyxn2Z78aW0

1Zonfrillo, M.R., Spicer, R.S., Lawrence, B.A. et al. Incidence and costs of injuries to children and adults in the United States. Inj. Epidemiol. 5,37 (2018). https://doi.org/10.1186/s40621-018-0167-6

About MultiStem®

MultiStem® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy’s potential for multidimensional therapeutic impact may distinguish it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. MultiStem represents a unique “off-the-shelf” stem cell product candidate that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon favorable outcome data, its novel mechanisms of action, and favorable and consistent tolerability data in clinical studies, we believe that MultiStem therapy may provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.

About MTEC

MTEC is a biomedical technology consortium collaborating with multiple government agencies under an agreement with the U.S. Army Medical and Materiel Command. The MTEC mission is to assist the Army’s Medical Research and Materiel Command by providing cutting-edge technologies and effective materiel life cycle management to transition medical solutions to industry.

About UTHealth

Established in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houston’s Health University and Texas’ resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School, and schools of biomedical informatics, biomedical sciences, dentistry, and public health. UTHealth includes the UTHealth Harris County Psychiatric Center, as well as the growing clinical practices UT Physicians, UT Dentists, and UT Health Services. The university’s primary teaching hospitals are Memorial Hermann-Texas Medical Center, Children’s Memorial Hermann Hospital, and Harris Health Lyndon B. Johnson Hospital. For more information, visit www.uth.edu.

About Athersys

Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations, including but not limited to, our ability to access our traditional financing sources on the same or reasonably similar terms as were available to us before the COVID-19 pandemic; the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke, and the Healios TREASURE and ONE-BRIDGE clinical trials in Japan evaluating the treatment in stroke and ARDS patients, respectively; the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of COVID-19 induced ARDS, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the impact of the COVID-19 pandemic on our ability to complete planned or ongoing clinical trials; the possibility that the COVID-19 pandemic could delay clinical site initiation, clinical trial enrollment, regulatory review and the potential receipt of regulatory approvals, payment of milestones under our license agreements and commercialization of one or more of our product candidates, if approved; the availability of product sufficient to meet commercial demand shortly following any approval, such as in the case of accelerated approval for the treatment of COVID-19 induced ARDS; the impact on our business, results of operations and financial condition from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of infectious disease in the United States; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the impact of the COVID-19 pandemic on the production capabilities of our contract manufacturing partners and our MultiStem trial supply chain; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors which could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the success of our efforts to enter into new strategic partnerships and advance our programs, including, without limitation, in North America, Europe and Japan; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 under Item 1A, “Risk Factors” and our other filings with the SEC. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Ivor Macleod

Chief Financial Officer

Tel: (216) 431-9900

[email protected]

Karen Hunady

Director of Corporate Communications & Investor Relations

Tel: (216) 431-9900

[email protected]

David Schull

Russo Partners, LLC

Tel: (212) 845-4271 or (858) 717-2310

[email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo
Posted on

Institutional Property Advisors Closes Two-Property $90.2 Million Multifamily Portfolio Sale in Southern Arizona

Institutional Property Advisors Closes Two-Property $90.2 Million Multifamily Portfolio Sale in Southern Arizona

TUCSON, Ariz.–(BUSINESS WIRE)–Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE: MMI), announced today the sale of a two-property multifamily portfolio in Tucson, Arizona. The properties are Equestrian, a 288-unit complex that sold for $47.7 million, or $165,625 per unit, and Ridgeline, a 272-unit property that traded for $42.5 million, which represents $156,250 per unit.

“Post-2000 constructed multifamily assets like Equestrian and Ridgeline are rarely available in North Tucson,” said Hamid Panahi, IPA first vice president. “These two communities provide new ownership with the opportunity to enhance revenue through the continued implementation of an apartment interior renovation program.” Panahi, along with Steve Gebing and Cliff David, IPA executive managing directors, represented the seller, Bascom Arizona Ventures, and procured the buyer, Bridge Investment Group. “Job growth and economic development should not be overlooked in Tucson with tremendous momentum in the aerospace and defense sector, high technology, bioscience, healthcare, mining technology, and logistics leading the way,” added Gebing. “There’s a reason internationally recognized companies like Raytheon, Caterpillar, and Amazon are attracted to the market.”

Both properties are located on West Linda Vista Boulevard in Northwest Tucson, close to Thornydale Retail Center, Thornydale Village, Tucson Premium Outlets and Pima Community College. Completed in 2008 on 13 acres, Equestrian has 18 residential buildings, a swimming pool, gas and charcoal grilling stations, assigned covered parking and detached garages. Apartments have nine-foot ceilings and the average unit size is 900 square feet. Ridgeline’s 17 residential buildings were constructed in 2002 and 2008 on 13 acres. The property has two resort-style swimming pools and the average apartment size is 821 square feet.

About Institutional Property Advisors (IPA)

Institutional Property Advisors (IPA) is a division of Marcus & Millichap (NYSE: MMI), a leading commercial real estate services firm in North America. IPA’s combination of real estate investment and capital markets expertise, industry-leading technology, and acclaimed research offer customized solutions for the acquisition, disposition and financing of institutional properties and portfolios. For more information, please visit www.institutionalpropertyadvisors.com.

About Marcus & Millichap, Inc.

With over 2,000 investment sales and financing professionals located throughout the United States and Canada, Marcus & Millichap is a leading specialist in commercial real estate investment sales, financing, research and advisory services. Founded in 1971, the firm closed 9,726 transactions in 2019 with a value of approximately $50 billion. Marcus & Millichap has perfected a powerful system for marketing properties that combines investment specialization, local market expertise, the industry’s most comprehensive research, state-of-the-art technology, and relationships with the largest pool of qualified investors. For additional information, please visit www.MarcusMillichap.com.

Gina Relva

Public Relations Director, Marcus & Millichap

510-999-1284

KEYWORDS: Arizona United States North America

INDUSTRY KEYWORDS: Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo
Posted on

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

Insulet to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference

ACTON, Mass.–(BUSINESS WIRE)–
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021 at 9:10 a.m. (Eastern Time)

To listen to the live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the audio webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: www.insulet.com and www.myomnipod.com.

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

[email protected]

Jason McGorman

Principal Investor Relations Analyst

(978) 600-7627

[email protected]

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Devices Health Diabetes General Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Tower Semiconductor and GMEMS Announce the Ramp to Mass Production of MEMS Microphones Products

                                                                                                 



 



Based on Tower’s flow in its high volume 200mm CMOS Fab, custom developed for GMEMS products enabling capacity expansion for high volume manufacturing





MIGDAL HAEMEK, Israel, and MILPITAS, California, December 21, 2020 – Tower Semiconductor (NASDAQ/TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, and GMEMS, a supplier of MEMS (Micro-Electro-Mechanical Systems) sensors and products to the telecommunications industry , today announced the ramp to mass production of GMEM’s MEMS microphones products on Tower’s 0.18um flow, custom developed for GMEMS products. Tailor designed for the rapidly growing demand of the earbuds and cellphone markets, GMEMS’s highly advanced microphones offer a substantially smaller solution than competition. Utilizing Tower’s advanced facilities and platforms provides high volume manufacturing and capacity assurance, enabling to meet these fast-growing market demands.

According to Yole Development, MEMS microphone market is expected to grow from $1.2B (5.8B units) in 2019 to $1.7B (9.3B units) in 2024 with 6.6% CAGR.

“We are very pleased to have partnered with Tower to enhance the manufacturing capability for our highly demanded microphone products. We chose Tower for its excellent reputation, superior technical capabilities, advanced technology platforms and its capability to manufacture MEMS at large scale due to the compatibility with its CMOS flow,” said Dr. Mark Wang, GMEMS CEO.  “The joint effort between GMEMS experts and Tower’s exceptional R&D team enabled a successful ramp to a stable high volume manufacturing of our products, as well as to set a roadmap for the development of our next-generation microphones“.

In addition to a very small die size, Tower’s flow offers multiple advantages for the manufacturing of the MEMS microphones including high dynamic range and high SNR (Signal to Noise Ratio), key features when addressing MEMS microphone market demands, especially for mobile devices.

“We are excited about our cooperation with GMEMS, a world leading company in its field, developing outstanding technology solutions and products. Our tight and well-aligned collaboration allowed to effectively ramp GMEMS excellent products to high volume mass production using best in class technology,” said Dr. Avi Strum, Senior Vice President and General Manager of Sensors & Displays Business Unit, Tower Semiconductor. “We look forward to accomplishing additional achievements together allowing to realize even greater market potential”.

For more information about Tower Semiconductor’s MEMS technology platform, please click here.

For more information about Tower Semiconductor’s process technology offerings, please click here or inquire at: [email protected]

For more information about GMEMS technology and products, please click here.

About GMEMS

GMEMS is a leading developer and provider of MEMS microphones, voice interface software and other MEMS products. With its core technical team having accumulated more than twenty years of working experience in MEMS acoustic sensor and noise suppression algorithms, GMEMS provides a one-stop solution for its end customers. Over the years, GMEMS has established itself as a leader in providing high performance MEMS microphones and voice processing algorithms for voice interface applications in telecommunication industry.

About Tower Semiconductor

Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM), the leader in high-value analog semiconductor foundry solutions, provides technology and manufacturing platforms for integrated circuits (ICs) in growing markets such as consumer, industrial, automotive, mobile, infrastructure, medical and aerospace and defense. Tower Semiconductor’s focuses on creating positive and sustainable impact on the world through long term partnerships and its advanced and innovative analog technology offering, comprised of a broad range of customizable process platforms such as SiGe, BiCMOS, mixed-signal/CMOS, RF CMOS, CMOS image sensor, non-imaging sensors, integrated power management (BCD and 700V), and MEMS. Tower Semiconductor also provides world-class design enablement for a quick and accurate design cycle as well as Transfer Optimization and development Process Services (TOPS) to IDMs and fabless companies. To provide multi-fab sourcing and extended capacity for its customers, Tower Semiconductor operates two manufacturing facilities in Israel (150mm and 200mm), two in the U.S. (200mm) and three facilities in Japan (two 200mm and one 300mm) through TPSCo. For more information, please visit www.towersemi.com.

Safe Harbor Regarding Forward-Looking Statements

This press release includes forward-looking statements, which are subject to risks and uncertainties. Actual results may vary from those projected or implied by such forward-looking statements. A complete discussion of risks and uncertainties that may affect the accuracy of forward-looking statements included in this press release or which may otherwise affect Tower’s business is included under the heading “Risk Factors” in Tower’s most recent filings on Forms 20-F, F-3, F-4 and 6-K, as were filed with the Securities and Exchange Commission (the “SEC”) and the Israel Securities Authority. Tower does not intend to update, and expressly disclaim any obligation to update, the information contained in this release. 

###

Tower Semiconductor Company Contact: Orit Shahar | +972-74-7377440 | [email protected]

Tower Semiconductor Investor Relations Contact: Noit Levy | +972-4-604-7066 | [email protected]

Attachment